




CV Template of KATRD International Conference 2021

Name	Dave Singh			
First Name	Dave	Last Name	Singh	
Country	UK			
Organization	University of Manchester /Medicines Evaluation Unit/ Manchester University NHS Foundation Trust			
Current Position	Professor of Clinical Pharmacology and Respiratory Medicine			

Educational Background

1979 – 1986 Colchester Royal Grammar School, Essex
1986 – 1989 Queens College, Cambridge University BA (Hons) Medical Sciences 2:1
1989 – 1991 Addenbrookes Medical School, Cambridge University MB, B.Chir.
General Medical Council Registration 3612309
MRCP (Royal College of Physicians of London; 1996)
MD (University of Manchester; 2002)
CCST Respiratory medicine & clinical pharmacology (2003)

Professional Experiences

Current appointment (since 2011)

Professor of Clinical Pharmacology & Respiratory Medicine, Division of Infection, Immunity & Inflammation, Respiratory research group, University of Manchester, Manchester, UK.

Honorary Consultant Respiratory Physician (Manchester University NHS Foundation Trust) & Medical Director at Medicines Evaluation Unit (Manchester University NHS Foundation Trust).

Previous Appointments:

2003 – 2011 Reader/Senior Lecturer in Clinical Pharmacology & Respiratory Medicine, University of Manchester

1996 – 2003 Registrar and Senior Registrar Chest Medicine & Clinical Pharmacology; North West Lung Centre, South Manchester University Hospitals Trust; Department of Pharmacology and Therapeutics, Liverpool University; Clinical Pharmacology, AstraZeneca Pharmaceuticals, Alderley Edge

1994 – 1996 Senior House Officer General Medicine: Withington Hospital, Christie Hospital, Clinical Pharmacology Unit AstraZeneca Pharmaceuticals.

1993 – 1994 Senior House Officer General Medicine, Warrington District General

1993 Senior House Officer A&E, Manchester Royal Infirmary

1992 – 93 House Officer Surgery, Colchester District General Hospital; General Medicine, Addenbrookes Hospital, Cambridge



Professional Organizations

FBPhS (Fellow of the British Pharmacology Society; 2019)

FERS (Fellow of the European Respiratory Society; 2019)

Main Scientific Publications

Rabe KF, Martinez FJ, Ferguson GT, Wang C, **Singh D**, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P; ETHOS Investigators. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. *N Engl J Med.* 2020;383:35-48.

Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, **Singh D**, Sin DD, Vogelmeier CF, Sciruba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators. Benralizumab for the Prevention of COPD Exacerbations. *N Engl J Med.* 2019;381:1023-1034

Virchow JC, Kuna P, Paggiaro P, Papi A, **Singh D**, Corre S, Zuccaro F, Vele A, Kots M, Georges G, Petruzzelli S, Canonica GW. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. *Lancet.* 2019;394:1737-1749

Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, **Singh D**. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. *Lancet Respir Med.* 2019;7:745-756

Postma DS, Brightling C, Baldi S, Van den Berge M, Fabbri LM, Gagnatelli A, Papi A, Van der Molen T, Rabe KF, Siddiqui S, **Singh D**, Nicolini G, Kraft M; ATLANTIS study group. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. *Lancet Respir Med.* 2019;7:402-416

Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, **Singh D**, Tabberer M, Wise RA, Pascoe SJ; IMPACT Investigators. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. *N Engl J Med.* 2018;378:1671-1680.

Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, **Singh D**. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. *Lancet.* 2018;391:1076-1084

Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, **Singh D**. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. *Lancet.* 2017;13;389:1919-1929.

Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β 2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. *Lancet.* 2016;388:963-73
